Scott Pollack, MD
Gastroenterology · Marrero, LANPI 1366633166
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Phathom Pharmaceuticals, Inc. accounts for 62.9% of it on its own, with 34 other manufacturers making up the rest. Among gastroenterology clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 519 payments — averaging $123.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Phathom Pharmaceuticals, Inc.$40K
- Laborie Medical Technologies Corp.$12K
- Medtronic$3K
- AbbVie$2K
- Gastrogpo, LLC$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$548
- plus $4K from 29 others
What the payments were for
- Consulting fees$11,95519%
- Speaking & faculty fees$32,82051%
- Travel & lodging$9,90915%
- Food & beverage$9,51915%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | 75 | $40,362 |
| Laborie Medical Technologies Corp. | 19 | $12,478 |
| Medtronic | 30 | $3,279 |
| AbbVie | 195 | $2,147 |
| Gastrogpo, LLC | 3 | $1,754 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 33 | $548 |
| Ardelyx, Inc. | 22 | $453 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $373 |
| Vital Connect, Inc | 1 | $302 |
| Sanofi | 14 | $261 |
| Bristol Myers Squibb | 12 | $208 |
| Pfizer | 11 | $193 |
| Covidien LP | 3 | $178 |
| Gilead | 8 | $169 |
| Johnson & Johnson | 10 | $158 |
| Anx Robotica Corp | 1 | $156 |
| Sight Sciences, Inc. | 1 | $151 |
| Celltrion USA Inc. | 7 | $139 |
| Regeneron Healthcare Solutions, Inc. | 5 | $125 |
| Fujifilm Healthcare Americas Corporation | 3 | $118 |
| Ipsen Biopharmaceuticals, Inc | 5 | $103 |
| Ironwood Pharmaceuticals, Inc | 4 | $77 |
| Boston Scientific | 3 | $67 |
| Merck | 4 | $60 |
| Daiichi Sankyo Inc. | 2 | $59 |
| Lilly USA, LLC | 4 | $57 |
| Organon | 3 | $44 |
| Aimmune Therapeutics, Inc. | 2 | $38 |
| Novo Nordisk | 2 | $37 |
| Braintree Laboratories, Inc. | 2 | $33 |
| Intercept Pharmaceuticals, Inc. | 2 | $28 |
| Mallinckrodt Hospital Products Inc. | 1 | $14 |
| Amgen | 1 | $14 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
| Micro-tech Endoscopy USA, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VOQUEZNA$39,476
- alpHaONE$8,551
- GI Genius$1,309
- ManoScan$330
- OMNI(R) SURGICAL SYSTEM (US)$151
- SION SURGICAL INSTRUMENT$151
How this compares
$64,203 in reported general payments places this provider in the 90th percentile of 254 gastroenterology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 15 | $409,415 |
| LinzessLinaclotide | 129 | $140,737 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 284 | $47,776 |
| VemlidyTenofovir Alafenamide | 13 | $23,596 |
| TrulancePlecanatide | 23 | $18,880 |
| Sucralfate | 55 | $12,166 |
| VoqueznaVonoprazan Fumarate | 14 | $9,057 |
| MotegrityPrucalopride Succinate | 13 | $8,732 |
| Pantoprazole Sodium | 569 | $5,249 |
| Lubiprostone | 45 | $4,694 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 31 | $3,871 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 21 | $3,485 |
| Esomeprazole Magnesium | 54 | $3,187 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 50 | $2,840 |
| Colestipol Hcl | 31 | $2,679 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $158 | $409,41515 claims |
| AbbVieLinzess | $2,147 | $140,737129 claims |
| GileadVemlidy | $169 | $23,59613 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $548 | $18,88023 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $40,362 | $9,05714 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $373 | $8,73213 claims |
| Braintree Laboratories, Inc.Suflave, Sutab | $33 | $7,35552 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 254 gastroenterology providers in Louisiana.
Other gastroenterology in Marrero
- Gary ReissMarrero$72K
- Jonathon ChapmanBaton Rouge$998K
- Conar FittonKenner$955K
- Gia LandryBaton Rouge$511K
- Charles MonierThibodaux$448K
- Nathaniel RanneyCovington$392K
- Georges CatinisMetairie$346K
- Humberto AguilarShreveport$313K
- Sarah GloverNew Orleans$274K
- Nisha LoganantharajNew Orleans$173K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.